3 critical SII vaccines to cost 20% more
The National Pharmaceuticals Pricing Authority has approved a 20% price hike for three critical vaccines produced by the Serum Institute of India. The decision aims to ensure market availability despite the company's monopolistic position in the vaccine sector.
Why it matters
This decision highlights the tension between regulating drug prices to ensure affordability and maintaining market supply for essential public health products.
3 critical SII vaccines to cost 20% more | India News - The Times of India
The article reports on a government regulatory decision and provides the rationale from both the regulator and the manufacturer without taking a stance.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in